| Cas No.: | 309-29-5 |
| Chemical Name: | 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one |
| Synonyms: | 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenylpyrrolidin-2-one;1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one;Doxapram;Dopram;Doxapram HCL;doxapram hydrochloride;Doxapramum;1-Ethyl-4-(2-morpholin-4-ylethyl)-3,3-di(phenyl)pyrrolidin-2-one |
| SMILES: | O=C1N(CC)CC(CCN2CCOCC2)C1(C3=CC=CC=C3)C4=CC=CC=C4 |
| Formula: | C24N2O2H30 |
| M.Wt: | 378.5072 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Doxapram inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively. |
| References: | [1]. Cotten JF, et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102(3), 779-785. [2]. Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568(1-2): p. 116-22. [3]. Anderson-Beck, R., et al., Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187(1): p. 25-8. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
